LEXARIA BIOSCIENCE CORP. Income (Loss) from Subsidiaries, before Tax
LEXARIA BIOSCIENCE CORP. (LEXX) reported Income (Loss) from Subsidiaries, before Tax of -$1.45 million for the 3-month period ending 2026-02-28, per its 10-Q filed 2026-04-13.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromSubsidiariesBeforeTax · last filed 2026-04-13
- LEXARIA BIOSCIENCE CORP. income (loss) from subsidiaries, before tax for the quarter ending 2026-02-28 was -$1.45M.
- LEXARIA BIOSCIENCE CORP. income (loss) from subsidiaries, before tax for the quarter ending 2025-11-30 was -$1.60M.
- LEXARIA BIOSCIENCE CORP. income (loss) from subsidiaries, before tax for the quarter ending 2025-02-28 was -$2.72M.
- LEXARIA BIOSCIENCE CORP. income (loss) from subsidiaries, before tax for the quarter ending 2024-11-30 was -$2.71M.
| Period end | Income (Loss) from Subsidiaries, before Tax 3 month | Income (Loss) from Subsidiaries, before Tax 6 month |
|---|---|---|
| 2026-02-28 | -$1.45M 10-Q · filed 2026-04-13 | -$3.05M 10-Q · filed 2026-04-13 |
| 2025-11-30 | -$1.60M 10-Q · filed 2026-01-13 | |
| 2025-02-28 | -$2.72M 10-Q · filed 2026-04-13 | -$5.42M 10-Q · filed 2026-04-13 |
| 2024-11-30 | -$2.71M 10-Q · filed 2026-01-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |